The Structural Genomics Consortium (SGC), an international public-private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.
The 1000th structure – known as JmjD2C – belongs to a class of proteins involved in epigenetic signalling, a key research area for the SGC. Epigenetics is the study of inherited changes in gene expression caused by proteins such as JmjD2C which 'switch' genes on or off. It is believed that a better understanding of epigenetics could lead to new treatments for a wide variety of diseases including cancer, diabetes,...more
A research team led by scientists from Oxford University (including the Structural Genomics Consortium, the Botnar Research Centre, the Weatherall Institute of Molecular Medicine, the Wellcome Building for Molecular Physiology, and the australian Diamantina Institute in Brisbane), have successfully deciphered the molecular mechanism how an ER protease (ERAP1) functions in a key step in cellular immunity- the processing of peptide antigens that are presented to Major Histocompatibilty Complex 1 (MHC1) molecules.
The team succeeded in determining several crystal structures that provide molecular snapshots along the complex catalytic path. Genome-wide association (GWAS)...more
The Structural Genomic Consortium (SGC) announced today that SGC and Cerep, a worldleading biotechnology company, will enter into a collaboration to develop open access biochemical and cell-based assays for the discovery of small molecule chemical probes and drug candidates on epigenetic targets. As part of the collaboration, Cerep will open a laboratory in Toronto from which it will offer its screening and profiling services.
The field of epigenetics is one of the most dynamic areas of biological research, spurring an increasing number of drug discovery programs in cancer, inflammation, metabolic and neuropsychiatric diseases. In the collaboration, the SGC and Cerep will...more
An intuitive and interactive tool to understand the structure of important biological macromolecules is now available for the readers of the Journal of Inherited Metabolic Disease (JIMD), the leading international journal covering all aspects of inborn errors of metabolism. Called iSee (for Interactive Structural Enhanced Experience), this molecular graphics tool will allow the readers to interactively fly over, zoom into and dive through 3D visualisations in atomic detail.
Recent advances in structural biology are helping other biomedical...more
This year the Wellcome Trust celebrates its 75th Anniversary.
As part of the celebrations, Wellcome Trust researchers from the SGC, the Department of Zoology, the University Museum of Natural History and the Museum of History of Science at the University of Oxford present a stimulating series of events.
The events will cover the way in which form and function are inextricably linked at the macroscopic, microscopic and molecular level, and its implications in biomedicine; the revolution of open access science in drug discovery and the history of X-ray crystallography in Oxford - the ground-breaking technique that enabled scientists to look into a protein at atomic level....more
2 March 2007, Toronto – The Structural Genomics Consortium (SGC), an international research effort set up in 2004 to determine the three-dimensional structures of proteins relevant to human disease, today posted its 375th protein structure in the public domain. The SGC, which is the largest international research project ever directed from Canada, operates from laboratories at University of Toronto, University of Oxford, and Karolinska Institutet, Stockholm. All three sites have achieved their output goals ahead of schedule.
Oxford, UK and Toronto, Canada, May 25, 2005: The Structural Genomics Consortium (SGC; www.thesgc.com), an Anglo-Canadian charitable consortium of public and private agencies, today announces it has delivered its first 50 human and malaria protein structures into the public domain on budget and 2 months ahead of schedule. New data that this provides to research will expedite the development of new and improved medicines and provide tools for researchers to study important diseases.
The human proteins whose structures were placed into the public domain by the SGC include new drug development targets across a range of diseases such...more